Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLOVAGE vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Not applicable (non-absorbed, gut lavage); systemic absorption minimal
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Polyethylene glycol 3350 is not absorbed systemically; no hepatic metabolism.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily fecal as unabsorbed drug; negligible renal excretion (<5%)
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Not applicable (minimal systemic absorption)
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Not applicable (limited to gastrointestinal tract)
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: <0.3% systemically absorbed
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
Contraindicated in GFR <30 m L/min/1.73 m²; for GFR 30-60 m L/min/1.73 m², use with caution due to risk of electrolyte imbalance, no dose adjustment recommended.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential fluid and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not indicated for patients under 18 years of age; no established weight-based dosing.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
No specific dose adjustment, but monitor for electrolyte disturbances, dehydration, and aspiration risk; consider split-dose regimen or lower volume if tolerated.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, seizures) in patients with impaired renal function, dehydration, or those taking medications affecting electrolytes.
There is no FDA black box warning for ALPHACAINE.
Monitor for fluid and electrolyte disturbances, especially in elderly, debilitated, or renal impaired patients. Use with caution in patients with gastrointestinal obstruction, ileus, or severe colitis.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis or megacolon, hypersensitivity to any component.
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Only clear liquids (e.g., water, clear broth, black coffee/tea, clear juices) are allowed during bowel preparation. Avoid all solid foods, dairy products, red or purple liquids, and alcohol. Do not consume any food containing pulp or seeds.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Due to lack of systemic absorption, excretion into breast milk is negligible. Colovage is considered compatible with breastfeeding. M/P ratio: not applicable.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No dose adjustment necessary; pharmacokinetics unchanged as drug is not absorbed.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
COLOVAGE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is a high-volume colon cleansing preparation. Ensure adequate hydration before, during, and after use. Monitor for electrolyte disturbances in patients with renal impairment or those taking diuretics. Split-dose regimen improves tolerance and cleansing quality. Avoid use in patients with gastrointestinal obstruction, perforation, or toxic megacolon.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Follow the split-dose regimen exactly as prescribed to achieve optimal bowel cleansing.,Drink additional clear liquids as directed to prevent dehydration.,Do not eat any solid food while taking the preparation; only clear liquids are allowed.,Expect frequent, watery stools; stay near a restroom.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLOVAGE vs ALPHACAINE, answered by our medical review team.
COLOVAGE is a Osmotic Laxative that works by COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLOVAGE and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLOVAGE is: 4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLOVAGE and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLOVAGE is classified as Category C. Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.